MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition

Inhibiting myocardial cell death and fibrosis after acute myocardial infarction (AMI via permanent LAD ligation) is attenuated with treatment post-MI with a cell permeant peptide targeting MAPK kinase 2 (MK2)-MMI-0100. Daily MMI-0100 treatment results in improved function and decreased LV dilation in the 2 weeks post-AMI investigated.185